Skip to content

Effect of oliceridine versus sufentanil for patient-controlled intravenous analgesia after laparoscopic radical resection for colorectal cancer

Effect of oliceridine versus sufentanil for patient-controlled intravenous analgesia after laparoscopic radical resection for colorectal cancer

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500105354
Enrollment
Unknown
Registered
2025-07-02
Start date
2025-07-02
Completion date
Unknown
Last updated
2025-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The pain after laparoscopic radical resection for colorectal cancer

Interventions

The group of sufentanil 2µg/kg:The formula for the postoperative intravenous patient-controlled analgesia pump is sufentanil 2 µg/kg + flurbiprofen axetil 200 mg, with a total volume of 150 ml.
The group of oliceridine 0.4mg/kg:The formula for the postoperative intravenous patient-controlled analgesia pump is oliceridine 0.4mg/kg + flurbiprofen axetil 200 mg, with a total volume of 150 ml.
The group of oliceridine 0.6mg/kg:The formula for the postoperative intravenous patient-controlled analgesia pump is oliceridine 0.6mg/kg + flurbiprofen axetil 200 mg, with a total volume of 150 ml.
The group of oliceridine 0.8mg/kg:The formula for the postoperative intravenous patient-controlled analgesia pump is oliceridine 0.8mg/kg + flurbiprofen axetil 200 mg, with a total volume of 150 ml.

Sponsors

Gansu Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Patients undergoing elective laparoscopic radical surgery for colorectal cancer; 2.Aged 18-75 years; 3.ASA classification I, II, or III; 4.BMI <= 30 kg/m^2; 5.Patients or their family members have been fully informed about the study and have signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1.Allergies to drugs used during anesthesia and postoperative analgesia; 2.History of chronic pain or long-term use of opioids; 3.Long-term use of antidepressants or sedatives; 4.Intraoperative conversion to open surgery; 5.Emergency surgery performed due to acute intestinal obstruction, intestinal bleeding, intestinal perforation, etc.; 6.Presence of severe respiratory diseases (e.g., severe COPD, bronchial asthma), severe cardiovascular diseases (e.g., ejection fraction 442 µmol/L); 7.Presence of active peptic ulcers; 8.Severe mental or neurological disorders affecting the patient's ability to understand and follow the study protocol (MMSE score < 26).

Design outcomes

Primary

MeasureTime frame
Postoperative NRS pain score;

Secondary

MeasureTime frame
The time of the first press of the PCIA pump after surgery.;Total number of presses of the PCIA pump by the patient on POD1 and POD2.;Total amount of sufentanil used for rescue analgesia on POD1 and POD2.;Record the occurrence of adverse events on POD1 and POD2, including the degree of nausea and vomiting, level of sedation, incidence of respiratory depression, incidence of hypotension, incidence of bradycardia, and incidence of pruritus.;Time of first flatus after surgery.;Time of first bowel movement after surgery.;Number of bowel sounds per minute at 12h, 24h, 36h, and 48h post-surgery.;QoR-15 scores of the patient at 24h and 48h post-surgery.;VAS pain satisfaction score at 48h post-surgery.;

Countries

China

Contacts

Public ContactYan Wenjun

Gansu Provincial Hospital

13893370700@163.com+86 138 9337 0700

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026